News

Article

Pantheon Vision and Eyedeal Medical enter collaborative agreement to develop bioengineered corneal implant

Key Takeaways

  • Pantheon Vision and Eyedeal Medical collaborate to commercialize bioengineered corneal implants, targeting corneal blindness elimination.
  • Pantheon has engaged in multiple FDA meetings to support a Premarket Approval submission for their corneal implants.
SHOW MORE

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

(Image Credit: AdobeStock/David)

(Image Credit: AdobeStock/David)

Pantheon Vision has entered into a collaboration agreement with manufacturer Eyedeal Medical to advance the production and commercialization of Pantheon Vision’s bioengineered corneal implant.

At the beginning of 2025, Pantheon completed its third meeting with the US Food and Drug Administration (FDA) review team, after previously completing 2 pre-submission meetings with the organization. The meetings were for guidance on the initial stages of pre-clinical and clinical work supporting a Premarket Approval (PMA) submission for the company’s bioengineered corneal implants to eliminate corneal blindness.

Guo Guangxu, founder and CEO of Eyedeal Medical, and John Sheets, Jr, PhD, president and CEO of Pantheon Vision commented on the partnership in a press release from Pantheon.

“Pantheon Vision has assembled a world-leading ophthalmic design team whose groundbreaking mindset has enabled the bold development of a revolutionary single-piece polymer artificial cornea for vision restoration,” said Guangxu. “This innovation, upon commercialization, will fundamentally eliminate the need for corneal donations while bringing new hope to global patients requiring corneal transplantation."

“This agreement is a critical step for Pantheon Vision as we advance our mission of developing a bioengineered corneal solution to treat and restore vision for people around the world,” said Sheets Jr “We are grateful for the partnership with Eyedeal Medical and are extremely optimistic that together we can create an innovative solution that will provide meaningful benefits to patients suffering from corneal blindness.”

Human donated tissue has less than a 50% success rate at 5 years, among other issues such as short shelf life and insufficient tissue available. The company aims to tackle these issues with its bioengineered corneal implants.

References:
  1. Pantheon Vision signs collaboration agreement with Eyedeal Medical to develop bioengineered corneal implant. Published March 27, 2025. Accessed March 27, 2025. https://www.businesswire.com/news/home/20250327308058/en/Pantheon-Vision-Signs-Collaboration-Agreement-with-Eyedeal-Medical-to-Develop-Bioengineered-Corneal-Implant

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.